Histamine H1 receptor antagonists in the treatment of insomnia: Is there a rational basis for use?

CNS Drugs

Volumn 13, Issue 2, 2000, Pages 87-96

  Monti, Jaime M ^a,c   Monti, Daniel ^b  

^a HOSPITAL DE CLÍNICAS   (Uruguay)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c NONE   (Uruguay)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHLORPHENIRAMINE; DIPHENHYDRAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; LORAZEPAM; MEPYRAMINE; PROMETHAZINE; TRIPROLIDINE; ZALEPLON; ZOLPIDEM;

ARTICLE; ATAXIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DRUG EFFICACY; DYSARTHRIA; HUMAN; INSOMNIA; MOTOR DYSFUNCTION; NEUROMODULATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REM SLEEP; SEDATION;

EID: 0034094374     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200013020-00002     Document Type: Article

References (71)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington DC: American Psychiatric Association, 1994
2. Bovet D. Introduction to antihistamine agents and antergan derivatives. Ann N Y Acad Sci 1950; 50: 1089-126
3. Harvey SC. Hypnotics and sedatives: the barbiturates. In: Goodman LS, Gilman A, editors. The pharmacological basis of therapeutics. New York (NY): MacMillan, 1975: 102-23
4. Kales A, Kales JD. Evaluation and treatment of insomnia. 1st ed. New York (NY): Oxford University Press, 1984
5. Monti JM, Monti D. Pharmacological treatment of chronic insomnia. CNS Drugs 1995; 4 (3): 182-94
6. Panula P, Pirvola U, Auvinen S, et al. Histamine immunoreactive nerve fibers in the rat brain. Neuroscience 1989; 28: 585-610
7. Panula P, Airaksinen MS, Pirvola U, et al. A histamine-containing neuronal system in human brain. Neuroscience 1990; 34: 127-32
8. Pollard H, Bouthenet ML. Autoradiographic visualization of the three histamine receptor subtypes in the brain. In: Schwartz JC, Haas HL, editors. The histamine receptor. New York (NY): Wiley-Liss, 1992: 179-92
9. 3-receptor and control of histamine release. In: Schwartz JC, Haas HL, editors. The histamine receptor. New York (NY): Wiley-Liss, 1992: 145-59
10. 3) visualized in the brain of human and non-human primates. Brain Res 1990; 526: 322-7
11. Vanni-Mercier G, Sakai K, Salvert D, et al. Waking-state specific neurons in the posterior hypothalamus of the cat. In: Koella WP, Rüther E, Schulz H, editors. Sleep '84. Stuttgart: Fischer, 1985: 238
12. Orr EL, Quay WB. Hypothalamic 24-hour rhythm in histamine, histidine decarboxylase and histamine-N-methyltransferase. Endocrinology 1975; 96: 941-5
13. Ranson SW. Somnolence caused by hypothalamic lesion in the monkey. Arch Neurol Psychiatry 1939; 41: 1-2
14. Naquet R, Denavit M, Albe-Fessard D. Comparaison entre le rôle du subthalamus et celui des différentes structures bulbomésencéphaliques dans le maintien de la vigilance. Electroencephalogr Clin Neurophysiol 1966; 20: 149-64
15. McGinty DJ. Somnolence, recovery and hyposomnia following ventromedial diencephalic lesions in the rat. Electroencephalogr Clin Neurophysiol 1969; 26: 70-9
16. Wolf P, Monnier M. Electroencephalographic, behavioral and visceral effects of intraventricular infusion of histamine in the rabbit. Agents Actions 1973; 3: 193
17. Monti JM. Pharmacology of the histaminergic system. In: Kales A, editor. The pharmacology of sleep. Berlin: Springer, 1995: 117-42
18. 1 receptors. Neuroscience 1998; 87: 479-87
19. 1-receptor agonist 2-(3-trifluoromethylphenyl)histamine increases waking in the rat. Eur Neuropsychopharmacol 1994; 4: 459-62
20. 2-histamine receptor agonists and antagonists on sleep and wakefulness in the rat. J Neural Transm 1986; 66: 1-11
21. Wauquier A, Van den Broeck WAE, Awouter F, et al. A comparison between astemizole and other antihistamines on sleep-wakefulness cycles in dogs. Neuropharmacology 1981; 20: 853-9
22. 3 receptor on sleep and wakefulness. Eur J Pharmacol 1991; 205: 283-7
23. 3 antagonist carboperamide (MR 16155) administration in rats. Neuropsychopharmacology 1996; 15: 31-5
24. Dringenberg HC, Vanderwolf CH. Involvement of direct and indirect pathways in electrocorticographic activation. Neurosci Biobehav Rev 1998; 22: 243-57
25. Babe KS, Serafin WE. Histamine, bradykinin, and their antagonists. In: Hardman JG, Goodman Gilman A, Limbird LE, editors. The pharmacological basis of therapeutics. New York (NY): McGraw-Hill, 1996: 581-96
26. 1-receptor antagonists: clinical pharmacology and therapeutics. J Allergy Clin Immunol 1989; 84: 845-61
27. Woodward JK. Pharmacology of antihistamines. J Allergy Clin Immunol 1990; 86: 606-12
28. 2 receptors. In: Schwartz JC, Haas HL, editors. The histamine receptor. New York (NY): Wiley-Liss, 1992: 1-56
29. Costa E, Silva JA, Chase M, Sartorius N, et al. An overview of insomnias and related disorders - recognition, epidemiology, and rational management. Sleep 1996; 19: 412-6
30. Wittchen HU, Zhao S, Kessler RC, et al. DSM-III-R generalized anxiety disorder in the national comorbidity survey. Arch Gen Psychiatry 1994; 51: 355-64
31. Uhlenhuth EH, Balter MB, Mellinger GD, et al. Symptom checklist syndromes in the general population: correlations with psychotherapeutic drug use. Arch Gen Psychiatry 1983; 40: 1167-73
32. Diagnostic Steering Committee. ICSD - international classification of sleep disorders: diagnostic and coding manual. Rochester (MN): American Sleep Disorders Association, 1990
33. Roth T, Roehrs TA, Vogel GW, et al. Evaluation of hypnotic medications. In: Prien RF, Robinson DS. Clinical evaluation of psychotropic drugs: principles and guidelines. New York (NY): Raven Press, 1994: 579-92
34. 2 antagonists. Neuropharmacology 1985; 24: 245-50
35. Saletu B, Grünberger J, Krupka M, et al. Comparative double-blind, placebo-controlled sleep laboratory studies of a combination of lorazepam and diphenhydramine (SM-1014) and its single components. Curr Ther Res 1987; 42: 1037-58
36. Risberg A-M, Risberg J, Ingvar DH. Effects of promethazine on nocturnal sleep in normal man. Psychopharmacologia 1975; 43: 279-84
37. Adam K, Oswald I. The hypnotic effect of an antihistamine: promethazine. Br J Clin Pharmacol 1986; 22: 715-7
38. Alford C, Rombaut N, Jones J, et al. Acute effects of hydroxyzine on nocturnal sleep and sleep tendency the following day: a C-EEG study. Human Psychopharmacol 1992; 7: 25-35
39. Rickels K, Morris RJ, Newman H, et al. Diphenhydramine in insomniac family practice patients: a double-blind study. J Clin Pharmacol 1983; 23: 235-42
40. Kudo Y, Kurihara M. Clinical evaluation of diphenhydramine hydrochloride for the treatment of insomnia in psychiatric patients: a double-blind study. J Clin Pharmacol 1990; 30: 1041-8
41. Sunshine A, Zinghelboim I, Laska E. Hypnotic activity of diphenhydramine, methapyrilene, and placebo. J Clin Pharmacol 1978; 18: 425-31
42. Borbély AA, Youmbi-Baldener G. Effect of diphenhydramine on subjective sleep parameters, and on motor activity during bedtime. Int J Clin Pharmacol Ther Toxicol 1988; 26: 392-6
43. Hindmarch I, Parrott AC. A repeated dose comparison of the side effects of five antihistamines on objective assessments of psychomotor performance, central nervous system arousal and subjective appraisals of sleep and early morning behavior. Arzneim-Forsch/Drug Res 1978; 28: 483-3
44. Monti JM. Sleep laboratory and clinical studies of the effects of triazolam, flunitrazepam and flurazepam in insomniac patients. Methods Find Exp Clin Pharmacol 1981; 3: 303-26
45. Bixler EO, Vgontzas AN, Kales A. Methodological issues in pharmacological studies of sleep. In: Kales A, editor. The pharmacology of sleep. Berlin: Springer, 1995: 323-43
46. Schweitzer PK, Muehlbach MJ, Walsh JK. Sleepiness and performance during three-day administration of cetirizine or diphenhydramine. J Allergy Clin Immunol 1994; 94: 716-24
47. Rosenthal L, Roehrs TA, Paxton J, et al. Tolerance to the sedative effects of antihistamines [abstract]. Sleep Res 1995; 24: 52
48. Bye CE, Claridge R, Peck AW, et al. Evidence for tolerance to the central nervous effects of the histamine antagonist, triprolidine, in man. Eur J Clin Pharmacol 1977; 12: 181-6
49. Levander S, Stahle-Bäckdahl M, Hägermark O. Peripheral antihistamine and central sedative effects of single and continuous oral doses of cetirizine and hydroxyzine. Eur J Clin Pharmacol 1991; 41: 435-9
50. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 1980; 10: 189-209
51. Cohen AF, Posner J, Ashby L, et al. A comparison of methods for assessing the sedative effects of diphenhydramine on skills related to driving. Eur J Clin Pharmacol 1984; 27: 477-82
52. White JM, Rumbold GR. Behavioral effects of histamine and its antagonists: a review. Psychopharmacology 1988; 95: 1-14
53. Gengo F, Gabos Ch, Miller JK. The pharmacodynamics of diphenhydramine-induced drowsiness and changes in mental performance. Clin Pharmacol Ther 1989; 45: 15-21
54. Rice VJ, Snyder HL. The effects of benadryl® and hismanal® on mood, physiological measures, antihistamine detection, and subjective symptoms. Aviat Space Environ Med 1993; 64: 717-25
55. Ramaekers JG, O'Hanlon JF. Acrivastine, terfenadine and diphenhydramine effects on driving performance as a function of dose and time after dosing. Eur J Clin Pharmacol 1994; 47: 261-6
56. Burns M, Shanaman JE, Shellenberger CH. A laboratory study of patients with chronic allergic rhinitis: antihistamine effects on skilled performance. J Allergy Clin Immunol 1994; 93: 716-24
57. Simons FER, Fraser TG, Reggin JD, et al. Adverse central nervous system effects of older antihistamines in children. Pediatr Allergy Immunol 1996; 7: 22-7
58. Nicholson AN, Stone BM. Antihistamines: impaired performance and the tendency to sleep. Eur J Clin Pharmacol 1986; 30: 27-32
59. 1-histamine receptor antagonist ebastine in 10, 20 and 30 mg dose, and triprolidine 10 mg on car driving performance. Br J Clin Pharmacol 1993; 36: 67-70
60. Kerr JS, Dunmore C, Hindmarch I. The psychomotor and cognitive effects of a new antihistamine, mizolastine, compared to terfenadine, triprolidine and placebo in healthy volunteers. Eur J Clin Pharmacol 1994; 47: 331-5
61. Nicholson AN. Effect of antihistamines brompheniramine maleate and triprolidine hydrochloride, on performance in man. Br J Clin Pharm 1979; 8: 321-4
62. Hindmarch I, Bhatti JZ. Psychomotor effects of astemizole and chlorpheniramine, alone and in combination with alcohol. Int Clin Psychopharmacol 1987; 2: 117-9
63. Walsh JK, Muehlbach MJ, Schweitzer PK. Simulated assembly line performance following ingestion of cetirizine or hydroxyzine. Ann Allergy 1992; 69: 195-200
64. Roehrs T, Tietz E, Zorick F. Daytime sleepiness and antihistamines. Sleep 1984; 7: 137-41
65. Roth T, Roehrs T, Koshorek G, et al. Sedative effects of antihistamines. J Allergy Clin Immunol 1987: 80: 94-8
66. Seidel WF, Cohen S, Bliwise NG, et al. Direct measurement of daytime sleepiness after administration of cetirizine and hydroxyzine with a standardized electroencephalographic assessment. J Allergy Clin Immunol 1990; 86: 1029-33
67. Nicholson AN, Pascoe PA, Turner C, et al. Sedation and antihistamine H1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol 1991; 104: 270-6
68. Hurst M, Noble S. Zaleplon. CNS Drugs 1999; 11: 387-92
69. 3 receptor agonists. J Med Chem 1995; 38: 4070-9
70. 3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig. J Pharmacol Exp Ther 1998; 287: 43-50
71. 3 receptor agonists and antagonists. TIPS 1998; 19: 177-83